Journal article
Consensus report from the Food Allergy Research & Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit
Journal of allergy and clinical immunology, Vol.146(2), pp.244-249
08/2020
DOI: 10.1016/j.jaci.2020.05.027
PMID: 32505612
Abstract
Food allergy is a major health problem affecting 5% to 10% of the population in developed nations, including an estimated 32 million Americans. Despite the large number of patients suffering from food allergies, up until the end of January 2020, no treatment for food allergies had been approved by the US Food and Drug Administration. The only options were avoidance of food allergen triggers and acute management of allergic reactions. A considerable body of data exists supporting oral immunotherapy (OIT) as a promising, novel treatment option, including that for the now Food and Drug Administration–approved peanut OIT product Palforzia (Aimmune Therapeutics, Brisbane, Calif). However, data for long-term quality-of-life improvement with OIT varies, depending on the measures used for analysis. Like many therapies, OIT is not without potential harms, and burdens, and the evaluation of patient-specific risk-benefit ratio of food OIT produces challenges for clinicians and patients alike, with many unanswered questions. Food Allergy Research & Education organized the Oral Immunotherapy for Food Allergy Summit on November 6, 2019, modeled after the PRACTALL sessions between the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology to address these critical issues. Health care providers, patient representatives, researchers, regulators, and food allergy advocates came together to discuss OIT and identify areas of common ground as well as gaps in existing research and areas of uncertainty and disagreement. The purpose of this article was to summarize that discussion and facilitate collaboration among clinicians and patients to help them make better-informed decisions about offering and accepting OIT, respectively, as a therapeutic option.
Details
- Title: Subtitle
- Consensus report from the Food Allergy Research & Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit
- Creators
- Amber N. Pepper - University of South FloridaAmal Assa’ad - Cincinnati Children's Hospital Medical CenterMichael Blaiss - Augusta UniversityEmily Brown - Food Equality Initiative, Kansas City, Mo.Sharon Chinthrajah - Stanford UniversityChristina Ciaccio - University of ChicagoMary Beth Fasano - University of IowaRuchi Gupta - Lurie Children's HospitalNurry Hong - Food Allergy Research and EducationDavid Lang - Cleveland ClinicTodd Mahr - Gundersen Health SystemErin Malawer - ENT and AllergyAnita Roach - Food Allergy Research and EducationWayne Shreffler - Harvard UniversityScott Sicherer - Icahn School of Medicine at Mount SinaiKathleen Vickers - Food Allergy Research and EducationBrian P. Vickery - Emory UniversityRichard Wasserman - ENT and AllergyKimberley Yates - ENT and AllergyThomas B Casale - University of South Florida
- Resource Type
- Journal article
- Publication Details
- Journal of allergy and clinical immunology, Vol.146(2), pp.244-249
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.jaci.2020.05.027
- PMID
- 32505612
- ISSN
- 0091-6749
- eISSN
- 1097-6825
- Grant note
- Food Allergy Research & Education
- Language
- English
- Date published
- 08/2020
- Academic Unit
- Stead Family Department of Pediatrics; Rheumatology, Allergy, and Immunology; Immunology; Internal Medicine
- Record Identifier
- 9984354045402771
Metrics
5 Record Views